Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 7/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.52 |
| ▸ | CLK3 | P49761 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | GSK3B | P49841 | 3/20 | 0.52 |
| ▸ | WNT1 | P04628 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 4/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19065434 | 1.00 | CLK2 (0.52) | CLK2DYRK1ACLK3MAPTGSK3B | |
| SCHEMBL29675481 | 0.94 | BCHE (0.48) | CLK2DYRK1ACLK3MAPTGSK3B | |
| SCHEMBL19066087 | 0.94 | BCHE (0.48) | CLK2DYRK1ACLK3MAPTGSK3B | |
| SCHEMBL29675862 | 0.92 | ABL1 (0.48) | CLK2DYRK1ACLK3MAPTGSK3B | |
| SCHEMBL19065223 | 0.92 | ABL1 (0.48) | CLK2DYRK1ACLK3MAPTGSK3B | |
| SCHEMBL19065218 | 0.92 | NPY5R (0.48) | CLK2DYRK1ACLK3MAPTGSK3B | |
| SCHEMBL19065314 | 0.92 | MAPT (0.48) | CLK2DYRK1ACLK3MAPTGSK3B | |
| SCHEMBL29675270 | 0.92 | MAPT (0.48) | CLK2DYRK1ACLK3MAPTGSK3B | |
| SCHEMBL19065241 | 0.90 | NPY5R (0.46) | CLK2DYRK1ACLK3MAPTGSK3B | |
| SCHEMBL31181514 | 0.90 | NPY5R (0.46) | CLK2DYRK1ACLK3MAPTGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792256-B1 | PYRIDINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2024-10-23 | — | — | EP | claimed |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-04-09 | — | — | US | disclosed |
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | CLK2 1556/4885DYRK1A 2066/4885CLK3 2555/4885 |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | CLK2 1556/4885DYRK1A 2066/4885CLK3 2555/4885 |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | CLK2 1556/4885DYRK1A 2066/4885CLK3 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.